Actinium Pharmaceuticals to Present at SNMMI 2026 Highlighting ATNM-400 Innovations
Actinium Pharmaceuticals, Inc. has announced its participation in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, where it will present three key abstracts focusing on ATNM-400, a novel Actinium-225 antibody radioconjugate. The meeting is scheduled for May 30 to June 2, 2026, in Los Angeles, California.
ATNM-400 displays promising potential in various cancer types, notably non-small cell lung cancer (NSCLC) and prostate cancer. New data reveal its efficacy in KRAS-mutated NSCLC models, indicating its potential as a mutation-agnostic therapy, a significant advancement in overcoming resistance to current EGFR- and KRAS-targeted treatments. Furthermore, ATNM-400 exhibits potential across a spectrum of prostate cancers, irrespective of PSMA expression levels, thus addressing limitations in existing PSMA-targeted therapies.
Additionally, Actinium Pharmaceuticals will present data on radioconjugate optimization, specifically focusing on improving tumor targeting and pharmacokinetics by adjusting the chelator-to-antibody ratio (CAR) for 225Ac-labeled antibodies. This innovation supports the ongoing development of ATNM-400, underscoring Actinium's innovative approach to radiochemistry and its broader therapeutic pipeline.
At SNMMI 2026, the first presentation, titled "ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Potent PSMA-Independent Efficacy in Prostate Cancer Models," is scheduled for June 2. This presentation will explore ATNM-400's efficacy in various prostate cancer settings.
The second presentation, "ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Durable, Mutation-Agnostic Anti-Tumor Activity in Non-Small Cell Lung Cancer Models," will occur concurrently. It will detail the compound's ability to target challenging lung cancer mutations effectively.
The final presentation, "Optimizing Chelator-to-Antibody Ratio Improves Tumor Targeting and Pharmacokinetics of 225Ac-Labeled Antibodies," is set for May 31 and will discuss advancements in drug delivery systems that could enhance treatment outcomes.
Actinium's CEO, Sandesh Seth, emphasized the significance of these findings as the company prepares for clinical trials with ATNM-400. These studies mark a step forward in developing highly specialized radiotherapies targeting difficult-to-treat solid tumors, reflecting substantial commercial potential in oncology. The presentations at SNMMI are a testament to Actinium's commitment to advancing cancer treatment options with innovative radioconjugates.